CN1413594A - Medicine for prevention and curing reangiostenosis - Google Patents
Medicine for prevention and curing reangiostenosis Download PDFInfo
- Publication number
- CN1413594A CN1413594A CN 02132755 CN02132755A CN1413594A CN 1413594 A CN1413594 A CN 1413594A CN 02132755 CN02132755 CN 02132755 CN 02132755 A CN02132755 A CN 02132755A CN 1413594 A CN1413594 A CN 1413594A
- Authority
- CN
- China
- Prior art keywords
- medicine
- treatment
- vascular restenosis
- arsenic trioxide
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
Abstract
A medicine for preventing and treating reangiostenosis is disclosed, which is just the As2O3. It is applied by coating it on the surface of an alloy scaffold and the scaffold is then implantated in the damaged vessel. Its advantages are no toxic, and high effect.
Description
Technical field: the present invention relates to a kind of medicine of preventing and treating vascular restenosis behind the interventional therapy.
Background technology: along with the raising of living standards of the people and the arrival of social senilization, the narrow and occlusive pathological changes of cardiovascular and cerebrovascular vessel, the peripheral vessels that is caused by atherosclerosis constantly increases.Interventional therapy is the effective means of treatment angiostenosis and occlusive pathological changes, but interventional therapy postoperative restenosis incidence rate is up to 30%～50%, the interventional therapy combined bracket is implanted the postoperative restenosis incidence rate and is reached 14%～34%, and the control restenosis is the key that improves curative effect.The present whole body system medication of using is as vasodilators such as anticoagulant, anti-platelet agents, lipid lowerers, angiotensin converting enzyme inhibitors, the drug level that obtains at the local damage place is low, do not have the significantly effect of control restenosis, thereby clinical practice to no effect.
Summary of the invention: the invention provides a kind of medicine of treatment of vascular restenosis, this medicine has solved with the problem that occurs vascular restenosis after intervention ruling by law treatment angiostenosis and the occlusive pathological changes.The present invention is with the application of arsenic trioxide as the medicine of the topical of preparation treatment of vascular restenosis.The medicine of this treatment of vascular restenosis is made up of the composition of following percentage by weight: arsenic trioxide 0.001～5, binding agent 0.5～10, organic solvent 85～99.4.Above-mentioned binding agent is the left-handed lactobionic acid of poly, poly ammonia or poly urethane fat urea.Above-mentioned organic solvent is methanol, acetone, dimethyl sulfoxide or chloroform.Above-mentioned arsenic trioxide is solid or liquid arsenic trioxide.The medicine of this treatment of vascular restenosis is the surface that is applied to alloy bracket 1 in the used blood vessel of interventional therapy.Prove through zoopery of the present invention: arsenic trioxide can suppress smooth muscle cell proliferation, suppresses neointimal hyperplasia, and promotes the smooth cell apoptosis.After endovascular alloy bracket coated medicine layer, implant the vessel injury place, medicine slowly discharges (consulting figure three) in blood vessel local damage place, the arsenic trioxide coating bracket can discharge arsenic trioxide and reach more than the two weeks in blood vessel, make local organization drug level height, the concentration of system's body is low, thereby free of toxic effects.This medicine has the effect of obvious suppression injury region vascellum endometrial hyperplasia, control restenosis.After using the medicine of treatment of vascular restenosis of the present invention, the restenosis after interventional therapy incidence rate is dropped to below 5%.
Description of drawings: Fig. 1 is the structural representation that has the interior alloy bracket 1 of blood vessel of medicine of the present invention, Fig. 2 is the section amplification figure of the wall scroll alloy silk 3 of alloy bracket 1 among Fig. 1, Fig. 3 be the band medicine blood vessel in alloy bracket in animal body time-the tissue substance concentration curve, Fig. 4 carries out zooperal blood vessel section contrast photo with medicine of the present invention (wherein the right side is the blood vessel of medicine of no use, the left side is for having used the blood vessel of medicine of the present invention), Fig. 5 is the effect picture that medicine of the present invention carries out experiment in vitro.
The specific embodiment one: the medicine of the treatment of vascular restenosis of present embodiment is made up of the composition of following percentage by weight: arsenic trioxide 0.001～5, the left-handed lactobionic acid 0.5～10 of poly, methanol 85～99.4.Said medicine is applied to the surface of alloy bracket 1 in the blood vessel, and the thickness that forms medicine film 2 behind the organic solvent evaporation in this medicine on alloy bracket 1 is 1.6～300 μ m.
The specific embodiment two: what present embodiment and the specific embodiment one were different is to replace the left-handed lactobionic acid of poly with poly ammonia, replaces methanol with acetone.Other composition is identical with the specific embodiment one.
The specific embodiment three: what present embodiment and the specific embodiment one were different is to replace the left-handed lactobionic acid of poly with poly urethane fat urea, replaces methanol by chloroform.Other form with
The specific embodiment one is identical.
(1) comparative zoopery of the present invention:
100 of band arsenic trioxide coating brackets, not with 100 of the coating brackets of arsenic trioxide, implant respectively in the arteries of rabbit, after six months, the restenosis rate 3% of band arsenic trioxide coating bracket, average inner film thickness 666 μ m, not with the restenosis rate of the coating bracket of arsenic trioxide be 32%, average inner film thickness 1226 μ m.(see figure 4).
(2) experiment in vitro of the present invention:
0.001～1% arsenic trioxide adds in the human smooth muscular cells of In vitro culture, and smooth muscle cell is suppressed in mitotic phase, promotes the smooth muscle cell apoptosis.A large amount of as can be seen from Figure 5 smooth muscle cell apoptosis, kernel is dyed yellow, visible karyopycnosis, karyolysis (amplification 3.3 * 100).
Claims (7)
1, the medicine of treatment of vascular restenosis is characterized in that it is with the application of arsenic trioxide as the medicine of the topical of preparation treatment of vascular restenosis.
2, the medicine of treatment of vascular restenosis according to claim 1 is characterized in that medicine is made up of the composition of following percentage by weight: arsenic trioxide 0.001～5, binding agent 0.5～10, organic solvent 85～99.4.
3, the medicine of treatment of vascular restenosis according to claim 2 is characterized in that above-mentioned binding agent is the left-handed lactobionic acid of poly, poly ammonia or poly urethane fat urea.
4, the medicine of treatment of vascular restenosis according to claim 2 is characterized in that above-mentioned organic solvent is methanol, acetone, dimethyl sulfoxide or chloroform.
5, the medicine of treatment of vascular restenosis according to claim 2 is characterized in that above-mentioned arsenic trioxide is solid or liquid arsenic trioxide.
6,, it is characterized in that medicine is the surface that is applied to alloy bracket (1) in the used blood vessel of interventional therapy according to the medicine of claim 2,3,4 or 5 described treatment of vascular restenosiss.
7, the medicine of treatment of vascular restenosis according to claim 6 is characterized in that going up the thickness that forms medicine film (2) at alloy bracket (1) behind the organic solvent evaporation in the medicine is 1.6～300 μ m.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02132755 CN1413594A (en) | 2002-08-07 | 2002-08-07 | Medicine for prevention and curing reangiostenosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02132755 CN1413594A (en) | 2002-08-07 | 2002-08-07 | Medicine for prevention and curing reangiostenosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1413594A true CN1413594A (en) | 2003-04-30 |
Family
ID=4746918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02132755 Pending CN1413594A (en) | 2002-08-07 | 2002-08-07 | Medicine for prevention and curing reangiostenosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1413594A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100360094C (en) * | 2005-10-21 | 2008-01-09 | 哈尔滨工程大学 | Blood stent covered with arsenic oxide(s) film and preparing method thereof |
| CN100371032C (en) * | 2004-01-16 | 2008-02-27 | 东南大学 | Re-stricture preventing medicinal sustained releasing bracket and its preparation |
| CN100434082C (en) * | 2006-03-21 | 2008-11-19 | 上海交通大学医学院 | Application of diarsenic trioxide in ion-exchange protein |
| WO2009067862A1 (en) | 2007-11-27 | 2009-06-04 | Beijing Amsimo Medical Co., Ltd | An arsenic trioxide medical elution scaffold |
| CN1669537B (en) * | 2003-12-19 | 2011-10-05 | 科迪斯公司 | Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury |
-
2002
- 2002-08-07 CN CN 02132755 patent/CN1413594A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1669537B (en) * | 2003-12-19 | 2011-10-05 | 科迪斯公司 | Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury |
| CN100371032C (en) * | 2004-01-16 | 2008-02-27 | 东南大学 | Re-stricture preventing medicinal sustained releasing bracket and its preparation |
| CN100360094C (en) * | 2005-10-21 | 2008-01-09 | 哈尔滨工程大学 | Blood stent covered with arsenic oxide(s) film and preparing method thereof |
| CN100434082C (en) * | 2006-03-21 | 2008-11-19 | 上海交通大学医学院 | Application of diarsenic trioxide in ion-exchange protein |
| WO2009067862A1 (en) | 2007-11-27 | 2009-06-04 | Beijing Amsimo Medical Co., Ltd | An arsenic trioxide medical elution scaffold |
| EP2213313A4 (en) * | 2007-11-27 | 2011-03-30 | Beijing Amsino Medical Co Ltd | An arsenic trioxide medical elution scaffold |
| US8518429B2 (en) * | 2007-11-27 | 2013-08-27 | Beijing Amsino Medical Co., Ltd. | Arsenic trioxide medical elution scaffold |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Biological applications of copper-containing materials | |
| Amukarimi et al. | Biodegradable magnesium‐based biomaterials: an overview of challenges and opportunities | |
| Ma et al. | Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies | |
| Indolfi et al. | Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury | |
| CA2425696C (en) | Coated medical devices for the treatment of vascular disease | |
| CA2561156A1 (en) | Bioresorbable stent with beneficial agent reservoirs | |
| CN102860890B (en) | Composite medicine carrying vessel stent and preparation method thereof | |
| Li et al. | Incorporating copper to biodegradable magnesium alloy vascular stents via a Cu (II)‐Eluting coating for synergistic enhancement in prolonged durability and rapid Re‐endothelialization | |
| EP2380528A1 (en) | Medicament eluting apparatus with micro-hole structure capable of storing and releasing multiple medicines and preparation method | |
| CN103948975A (en) | Targeted drug release intervened medical appliance and preparation method thereof | |
| CN100435756C (en) | Arsenic trioxide control release elution stent | |
| JP2014531933A (en) | Intervention medical device and manufacturing method thereof | |
| Kim et al. | Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model | |
| CN101485902B (en) | Biological degradable metal stent coated with rapamycin-probucol composite medicament | |
| JP2014530058A (en) | Intervention medical device and manufacturing method thereof | |
| Steffel et al. | Biological effects of drug-eluting stents in the coronary circulation | |
| CN1413594A (en) | Medicine for prevention and curing reangiostenosis | |
| CN106310395A (en) | Composite drug-loading stent and preparation method thereof | |
| CN101455863A (en) | Medicine eluting coronary stent | |
| Oh et al. | Nanofiber-coated drug eluting stent for the stabilization of mast cells | |
| US20120150282A1 (en) | Implant having a paclitaxel-releasing coating | |
| Hou et al. | Stent-based nitric oxide delivery reducing neointimal proliferation in a porcine carotid overstretch injury model | |
| EP3639830B1 (en) | Composite anti-restenosis drug for coronary drug-eluting stent, and controlled release system thereof | |
| CN108014379B (en) | Surface modification method for improving corrosion resistance of magnesium alloy intravascular stent | |
| Shishir et al. | Zinc as a potential bio-degradable temporary implant material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |